Betrixaban, a Factor Xa inhibitor, appeared to reduce bleeding incidences more than warfarin when given in a 40-milligram dose to patients who had a stroke or nonvalvular atrial fibrillation. The midstage study recorded similar bleeding incidences between warfarin and 60-milligram, as well as 80-milligram, formulations of betrixaban, which is being developed by Merck & Co. and Portola Pharmaceuticals.

Related Summaries